CERo Therapeutics Announces Clinical Update from CERTAIN-T Phase 1 CER-1236 Trial, Including Patient Undergoing Allogeneic Stem Cell Transplant Following Treatment
Fifth patient treated with CER-1236 underwent stem cell transplant following lack of response to prior therapies; Company initiates third planned cohort in ongoing Phase 1 study in hematologic malignancies
Fifth patient treated with CER-1236 underwent stem cell transplant following lack of response to prior therapies; Company initiates third planned cohort in ongoing Phase 1 study in hematologic malignancies
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.